Company: Alnylam Pharmaceuticals
Tags: compensation, culture
Two years at Alnylam in rare disease. Honest take: the science is exceptional, the culture is genuinely mission-driven in a way I haven't seen elsewhere, and patients and families remember you. The downside is the patient populations are tiny so pressure to find new patients is relentless. There are only so many TTR-amyloidosis patients in a territory and once you've found them you're in a holding pattern. Comp is competitive — I'm at $142k base with a 20% target bonus. But the growth trajectory is limited unless you're moving up. Good place to be if you care deeply about rare disease. Not ide
45 upvotes · 6 comments